Related Experiment Video
Updated: Feb 9, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
Published on: June 7, 2024
CNS cancer immunity cycle and strategies to target this for glioblastoma
Malaka Ameratunga1, Niamh Coleman1, Liam Welsh2
1Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.
Abstract:
Immunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of the central nervous system (CNS) has been lacking. There are several possible reasons for the relative lack of success of immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system and impairment of drug delivery into the CNS through the BBB. This review utilizes the cancer-immunity cycle as a conceptual framework through which the specific challenges associated with the development of immunotherapeutics for CNS malignancies can be viewed.
Insights
Immunotherapeutics show promise for solid tumors but face challenges in brain cancers like glioblastoma. This review explores why immunotherapies struggle in the central nervous system (CNS) and how to overcome these hurdles.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Research
Background:
- Immunotherapeutics have transformed solid tumor treatment.
- Checkpoint inhibitors have shown limited efficacy in central nervous system (CNS) malignancies.
- Glioblastoma presents unique challenges for immunotherapy.
Purpose of the Study:
- To review the challenges hindering immunotherapy success in CNS tumors.
- To utilize the cancer-immunity cycle as a framework for understanding these challenges.
- To identify potential strategies for improving immunotherapy in brain cancers.
Main Methods:
- Literature review utilizing the cancer-immunity cycle as a conceptual framework.
- Analysis of factors affecting immunotherapy in the CNS environment.
- Discussion of blood-brain barrier (BBB) implications for drug delivery and lymphocyte trafficking.
Main Results:
- The CNS immune microenvironment, particularly in glioblastoma, poses significant barriers.
- The blood-brain barrier (BBB) restricts effective drug delivery and immune cell infiltration.
- Current immunotherapeutic strategies face limitations in penetrating and functioning within the CNS.
Conclusions:
- Overcoming CNS-specific barriers is crucial for advancing brain cancer immunotherapy.
- Targeting the tumor microenvironment and enhancing drug delivery are key strategies.
- The cancer-immunity cycle provides a valuable lens for developing future CNS immunotherapeutics.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
What is the Immune System?
Humoral Immune Responses
What are Biogeochemical Cycles?
The Water Cycle
CNS Depressants: Alcohol and Nicotine

